Ambiq Micro CEO Esaka Fumihide sells $3.98m in company stock
Ambiq Micro CEO Esaka Fumihide divested $3.98 million worth of the company's common stock in September 2026. The sales took place on September 11 and September 15, 2026, with stock prices fluctuating between $58.95 and $64.05. This comes after a remarkable stock surge of 132% over the past six months and 114% year-to-date. The current stock price of $60.85 indicates potential overvaluation based on InvestingPro's Fair Value analysis.
On September 11, Esaka acquired 50,000 shares through options at $12.60 each, totaling $630,000. He then sold these shares in two blocks, selling 42,083 shares at a weighted average price of $63.2661 and 7,917 shares at $63.8583. The total value of these sales was approximately $3,167,993. Four days later, on September 15, Esaka acquired 13,500 shares by exercising options at $8.12 per share, spending $109,619.
He subsequently sold 3,785 shares at $59.5626, 9,615 shares at $60.5482, and 100 shares at $61 per share, yielding a total sale value of approximately $813,715. Post these transactions, Esaka directly owns 460,460 shares of Ambiq Micro. The semiconductor company, valued at $1.44 billion, has seen a 32% revenue growth over the past year, though it remains unprofitable with negative earnings per share.
For more comprehensive insights, investors can refer to the Pro Research Report available on InvestingPro. Ambiq Micro recently reported a 89.7% quarter-over-quarter revenue increase to $33.9 million, with full-year sales now projected at $135 million. Analysts have revised their price targets, with UBS at $73 and BofA Securities at $75, both maintaining a Neutral rating and an Underperform rating respectively, citing strong demand and momentum in new applications.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Healthstream CEO sells $4.25m in common stock investing.com